Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.
Highlights this week included:
US: CAFC : Single embodiment commercial success: In re Glatt Air Techniques (Patently-O) (Patents Post Grant Blog) (PharmaPatents) (IPBiz)
US: Reverse payment settlements return to the Supreme Court: Louisiana Wholesale Drug Co et al v Bayer et al (Patently-O) (FDA Law Blog)
Kaletra (Ritonavir, Lopinavir) – India: Abbott’s patent on AIDS medicine denied (IP Watch) (Spicy IP) (SiNApSE)
Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.
General
Steve Burrill makes predictions for the biotech industry in 25th annual report (Patent Docs)
Australia: ‘Innovation’ patents in Australia – AMI innovation patent and US investment (IPBiz)
Australia: Extension of patent term for pharmaceuticals in Australia: AAT decision in LTS Lohmann Therapie Systeme AG and Schwarz Pharma Ltd and Commissioner of Patents (Patent Baristas)
US: CAFC : Single embodiment commercial success: In re Glatt Air Techniques (Patently-O) (Patents Post Grant Blog) (PharmaPatents) (IPBiz)
US: Reverse payment settlements return to the Supreme Court: Louisiana Wholesale Drug Co et al v Bayer et al (Patently-O)
US: 32 State AGs urge U.S. Supreme Court to take on patent settlement agreements: Louisiana Wholesale Drug Co et al v Bayer et al (FDA Law Blog)
US: BIO joins 170 business, research institutions and organisations to urge caution in Microsoft v i4i case (PatentlyBIOtech)
US: Galderma wins important victory in fight against Leo’s psoriasis patent covering vitamin D, corticosteroid composition for ‘dermal use’ (Reexamination Alert)
US: Déjà vu! Senators follow House colleagues in making BPCIA exclusivity clarifications; New study suggests benefits of longer drug exclusivity period (FDA Law Blog)
US: BPCIA’s principal authors seek to clarify Congressional intent with respect to 12-year exclusivity period; PhRMA/BIO request ‘umbrella exclusivity’ (FDA Law Blog)
US: BIO’s IP priorities for 2011 (PatentlyBIOtech)
US: BIO survey shows support for DNA-based patents despite some reservations (Patent Docs)
US: Representatives send letter to FDA to explain data exclusivity provisions of biosimilars legislation (Patent Docs)
US: Top stories of 2010: #4 to #1 – gene patent debate; diagnostic methods; biosimilar regulatory pathway enacted; AMP v USPTO (Patent Docs)
Products
Celsentri (Maraviroc) – India: Natco seeks license from Pfizer to manufacture low-cost version of HIV drug (Spicy IP)
Fentora (Fentanyl Buccal) – US: Watson’s generic Fentora receives FDA approval (SmartBrief)
Kaletra (Ritonavir, Lopinavir) – India: Abbott’s patent on AIDS medicine denied (IP Watch) (Spicy IP) (SiNApSE)
Lovaza (Omega-3) – US: Pronova files patent infringement complaint against Apotex following Para IV certification (Patent Docs)
Naropin (Ropivacaine) – US: APP Pharmaceuticals files patent infringement complaint against Navinta following Para IV certification (Patent Docs)
Nebivolol – Netherlands: District Court The Hague interim judgment in Janssen Pharmaceutica v Pharmachemie and Mosadex (EPLAW)
Proscar (Finasteride) – France: TGI Paris: Dosage regime not patentable: Actavis v. Merck (EPLAW)
Synagis (Palivizumab) – US: PDL BioPharma loses in N D California: (IPBiz)
Taxotere (Docetaxel) – US: Aventis files patent infringement complaint against Accord following Para IV certification (Patent Docs)
Valturna (Aliskiren, Valsartan) – India: Novartis’ patent for anti-hypertension combination drug Valturn revoked (patentcircle)
Vibativ (Telavancin) – India: Application for Telavancin hydrochloride refused under s. 15 (patentcircle)
Yasmin (Drospirenone, Ethinylestradiol) – India: Application for contraceptive drug Yasmin refused in pre-grant opposition (patentcircle)